RxDoctor Payments Data

Gary Finstad, MD

Internal Medicine · Lake Isabella, CANPI 1184763633

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 53 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$720
  • AbbVie$167
  • Smith+Nephew$87
  • Novartis$54
  • Boehringer Ingelheim$32
  • Cycle Pharmaceuticals Inc$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$1,08999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK34$720
AbbVie8$167
Smith+Nephew3$87
Novartis3$54
Boehringer Ingelheim2$32
Cycle Pharmaceuticals Inc1$17
Exact Sciences1$15
Alnylam Pharmaceuticals Inc.1$13

How this compares

$1,104 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$172,635
Medicare patients
388
Services billed
1,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$162,401
EliquisApixaban71$81,925
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$80,958
JardianceEmpagliflozin44$55,127
OzempicSemaglutide33$42,888
XareltoRivaroxaban23$38,421
Breo ElliptaFluticasone/Vilanterol29$22,481
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$19,340
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$17,102
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen287$6,023
Albuterol Sulfate HfaAlbuterol Sulfate95$5,780
Ventolin HfaAlbuterol Sulfate33$2,969
Atorvastatin Calcium355$2,946
Gabapentin103$2,933
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Synthroid$167$163,23264 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$720$122,779136 claims
Boehringer IngelheimJardiance$32$55,12744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lake Isabella

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →